AID systems are becoming increasingly popular among people with type 1 diabetes (pwt1d). As part of the Diabetes Report, we asked Pwt1d (n=1920) and parents of children with type 1 diabetes (n=210) in three countries (Germany, Austria and Switzerland) about the expected consequences of the increased use of AID systems. On a 5-point Likert scale (1=strongly disagree - 5=strongly agree), respondents were rather indifferent regarding the need for training programs specifically for AID systems. In contrast, the expectation of increased autonomy among AID users was very positive. On the other hand, respondents were rather negative about the statements that many users do not get along with AID systems, that there is less contact with the diabetes team as a result, that diabetes therapy becomes riskier as a result of AID systems, or that treatment in a diabetes clinic becomes more superfluous as a result. Generally, parents of children with diabetes were even more positive about AID systems than pwt1d (all p<0.05), while there were no significant differences between the 3 countries (all p>0.05). Pwt1d or their parents expect greater autonomy through the use of AIDs, whereas negative expectations regarding th AID impact on future diabetes care were rather low.
N. Hermanns: Speaker's Bureau; Berlin-Chemie AG, Sanofi-Aventis Deutschland GmbH. Research Support; Sanofi-Aventis Deutschland GmbH. Speaker's Bureau; Roche Diabetes Care. Research Support; Roche Diabetes Care. Speaker's Bureau; Dexcom, Inc. Advisory Panel; Abbott Diagnostics, Ypsomed AG. D. Ehrmann: Advisory Panel; Dexcom, Inc. Speaker's Bureau; Dexcom, Inc., Sanofi-Aventis Deutschland GmbH. Advisory Panel; Roche Diabetes Care. Speaker's Bureau; Roche Diabetes Care, Berlin-Chemie AG. T. Roos: None. L. Heinemann: Stock/Shareholder; Science Consulting in Diabetes GmbH, Profil Institut für Stoffwechselforschung GmbH. Advisory Panel; embecta. Board Member; Lifecare A/S. Stock/Shareholder; diateam GmbH. B. Kulzer: Advisory Panel; Abbott Diagnostics, Berlin-Chemie AG, Dexcom, Inc., Sanofi, embecta, Novo Nordisk, Roche Diabetes Care. Speaker's Bureau; Bayer Inc., Insulet Corporation, Lilly Diabetes.
